Studies on metastatic melanoma demonstrated that autologous tumour-infiltrating lymphocytes (TILs), ex vivo-expanded in the presence of interleukin-2 (IL-2) and then reinoculated into the patients, may be exploited to induce a long-lasting (up to 3 years) disease regression [5,6]. This evidence concerns the gene IL2 and metastatic melanoma.